Cilostazol NDC 0093-2064

NDC codes

FDA NDC Directory

Product NDC (as listed)0093-2064Labeler and product segments. Claims need a package NDC.

Product NDC at billing width00093-2064Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
0093-2064-06	00093206406	60 TABLET in 1 BOTTLE (0093-2064-06)Marketed from Oct 24, 2012
0093-2064-50	00093206450	5000 TABLET in 1 BOTTLE (0093-2064-50)Marketed from Oct 24, 2012

How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Cilostazol
Generic name (nonproprietary): cilostazol
Active ingredients: Cilostazol — 100 mg/1
Dosage form: Tablet
Route: Oral
Labeler: Teva Pharmaceuticals USA, Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 077027
Marketing start: Oct 24, 2012
Listing expires: Dec 31, 2026
Other FDA classes: Phosphodiesterase 3 Inhibitors (Mechanism)
Identifiers: Product ID 0093-2064_01457771-0b8c-4f1b-8513-01ad09ac97ccSPL ID 01457771-0b8c-4f1b-8513-01ad09ac97ccSPL set ID a6292311-9cb2-49ff-b8bf-12e2dbd196cdRxCUI 242461, 242462UNII N7Z035406B
Pharmacologic class: Phosphodiesterase 3 Inhibitor

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N400093206406 followed by a unit qualifier and the quantity

Package 00093-2064-06. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jul 31, 2022. This label includes a boxed warning.

Indications (excerpt from the label)

Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance. Cilostazol tablets are a phosphodiesterase III inhibitor (PDE III inhibitor) indicated for the reduction of symptoms of intermittent claudication, as demonstrated by an increased walking distance ( 1 )

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 077027

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 077027
Product	Strength	Form · route	Labeler	Product NDC
Cilostazol	Cilostazol 50 mg/1	TabletOral	Bryant Ranch Prepack	63629-8796
Cilostazol	Cilostazol 100 mg/1	TabletOral	Bryant Ranch Prepack	63629-8795
Cilostazol	Cilostazol 50 mg/1	TabletOral	direct rx	72189-116
Cilostazol	Cilostazol 50 mg/1	TabletOral	Teva Pharmaceuticals USA, Inc.	0093-2065